Chapter title |
High-Throughput Cell Toxicity Assays
|
---|---|
Chapter number | 16 |
Book title |
High Throughput Screening
|
Published in |
Methods in molecular biology, January 2016
|
DOI | 10.1007/978-1-4939-3673-1_16 |
Pubmed ID | |
Book ISBNs |
978-1-4939-3671-7, 978-1-4939-3673-1
|
Authors |
David Murray, Lisa McWilliams, Mark Wigglesworth, Murray, David, McWilliams, Lisa, Wigglesworth, Mark |
Abstract |
Understanding compound-driven cell toxicity is vitally important for all drug discovery approaches. With high-throughput screening (HTS) being the key strategy to find hit and lead compounds for drug discovery projects in the pharmaceutical industry [1], an understanding of the cell toxicity profile of hit molecules from HTS activities is fundamentally important. Recently, there has been a resurgence of interest in phenotypic drug discovery and these cell-based assays are now being run in HTS labs on ever increasing numbers of compounds. As the use of cell assays increases the ability to measure toxicity of compounds on a large scale becomes increasingly important to ensure that false hits are not progressed and that compounds do not carry forward a toxic liability that may cause them to fail at later stages of a project. Here we describe methods employed in the AstraZeneca HTS laboratory to carry out very large scale cell toxicity screening. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 8 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 3 | 38% |
Researcher | 1 | 13% |
Student > Master | 1 | 13% |
Unknown | 3 | 38% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 25% |
Agricultural and Biological Sciences | 2 | 25% |
Biochemistry, Genetics and Molecular Biology | 1 | 13% |
Physics and Astronomy | 1 | 13% |
Unknown | 2 | 25% |